🇺🇸 FDA
Pipeline program

Lu AA21004

LuAA21004/OCT-001

Phase 3 small_molecule completed

Quick answer

Lu AA21004 for Major Depressive Disorder is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Major Depressive Disorder
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials